Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 26

1.

Gravin regulates centrosome function through PLK1.

Colicino EG, Garrastegui AM, Freshour J, Santra P, Post DE, Kotula L, Hehnly H.

Mol Biol Cell. 2018 Mar 1;29(5):532-541. doi: 10.1091/mbc.E17-08-0524. Epub 2017 Dec 27.

2.

Establishing an Integrative Medicine Program Within an Academic Health Center: Essential Considerations.

Eisenberg DM, Kaptchuk TJ, Post DE, Hrbek AL, O'Connor BB, Osypiuk K, Wayne PM, Buring JE, Levy DB.

Acad Med. 2016 Sep;91(9):1223-30. doi: 10.1097/ACM.0000000000001173.

3.

Mps1 Mediated Phosphorylation of Hsp90 Confers Renal Cell Carcinoma Sensitivity and Selectivity to Hsp90 Inhibitors.

Woodford MR, Truman AW, Dunn DM, Jensen SM, Cotran R, Bullard R, Abouelleil M, Beebe K, Wolfgeher D, Wierzbicki S, Post DE, Caza T, Tsutsumi S, Panaretou B, Kron SJ, Trepel JB, Landas S, Prodromou C, Shapiro O, Stetler-Stevenson WG, Bourboulia D, Neckers L, Bratslavsky G, Mollapour M.

Cell Rep. 2016 Feb 2;14(4):872-884. doi: 10.1016/j.celrep.2015.12.084. Epub 2016 Jan 21.

4.

Epidermal growth factor receptor as a therapeutic target in glioblastoma.

Kalman B, Szep E, Garzuly F, Post DE.

Neuromolecular Med. 2013 Jun;15(2):420-34. doi: 10.1007/s12017-013-8229-y. Epub 2013 Apr 11. Review.

PMID:
23575987
5.

A model of integrative care for low-back pain.

Eisenberg DM, Buring JE, Hrbek AL, Davis RB, Connelly MT, Cherkin DC, Levy DB, Cunningham M, O'Connor B, Post DE.

J Altern Complement Med. 2012 Apr;18(4):354-62. doi: 10.1089/acm.2011.0408. Epub 2012 Mar 28.

6.

Bay846, a new irreversible small molecule inhibitor of EGFR and Her2, is highly effective against malignant brain tumor models.

Longo SL, Padalino DJ, McGillis S, Petersen K, Schirok H, Politz O, Canute GW, Post DE.

Invest New Drugs. 2012 Dec;30(6):2161-72. doi: 10.1007/s10637-011-9784-4. Epub 2011 Dec 29.

PMID:
22203214
7.

Development of an oncolytic herpes simplex virus using a tumor-specific HIF-responsive promoter.

Longo SL, Griffith C, Glass A, Shillitoe EJ, Post DE.

Cancer Gene Ther. 2011 Feb;18(2):123-34. doi: 10.1038/cgt.2010.62. Epub 2010 Oct 8.

8.

Second-generation HIF-activated oncolytic adenoviruses with improved replication, oncolytic, and antitumor efficacy.

Cherry T, Longo SL, Tovar-Spinoza Z, Post DE.

Gene Ther. 2010 Dec;17(12):1430-41. doi: 10.1038/gt.2010.100. Epub 2010 Jul 22.

9.

A regional human services authority's rapid needs assessment of evacuees following natural disasters.

Post DE, Kasofsky JM, Hunte CN, Diaz JH.

Am J Disaster Med. 2008 Sep-Oct;3(5):253-64.

PMID:
19069029
10.

Targeted cancer gene therapy using a hypoxia inducible factor dependent oncolytic adenovirus armed with interleukin-4.

Post DE, Sandberg EM, Kyle MM, Devi NS, Brat DJ, Xu Z, Tighiouart M, Van Meir EG.

Cancer Res. 2007 Jul 15;67(14):6872-81. Erratum in: Cancer Res. 2007 Sep 1;67(17):8422-3.

12.

Addition of choice of complementary therapies to usual care for acute low back pain: a randomized controlled trial.

Eisenberg DM, Post DE, Davis RB, Connelly MT, Legedza AT, Hrbek AL, Prosser LA, Buring JE, Inui TS, Cherkin DC.

Spine (Phila Pa 1976). 2007 Jan 15;32(2):151-8.

PMID:
17224808
13.

Cancer scene investigation: how a cold virus became a tumor killer.

Post DE, Shim H, Toussaint-Smith E, Van Meir EG.

Future Oncol. 2005 Apr;1(2):247-58. Review.

PMID:
16555996
14.

PTEN and hypoxia regulate tissue factor expression and plasma coagulation by glioblastoma.

Rong Y, Post DE, Pieper RO, Durden DL, Van Meir EG, Brat DJ.

Cancer Res. 2005 Feb 15;65(4):1406-13.

15.

Genetic and hypoxic regulation of angiogenesis in gliomas.

Kaur B, Tan C, Brat DJ, Post DE, Van Meir EG.

J Neurooncol. 2004 Nov;70(2):229-43. Review.

PMID:
15674480
16.

Cancer therapy with a replicating oncolytic adenovirus targeting the hypoxic microenvironment of tumors.

Post DE, Devi NS, Li Z, Brat DJ, Kaur B, Nicholson A, Olson JJ, Zhang Z, Van Meir EG.

Clin Cancer Res. 2004 Dec 15;10(24):8603-12.

17.

Use of replicating oncolytic adenoviruses in combination therapy for cancer.

Chu RL, Post DE, Khuri FR, Van Meir EG.

Clin Cancer Res. 2004 Aug 15;10(16):5299-312. Review.

18.

Tumor-specific gene expression using the survivin promoter is further increased by hypoxia.

Yang L, Cao Z, Li F, Post DE, Van Meir EG, Zhong H, Wood WC.

Gene Ther. 2004 Aug;11(15):1215-23.

19.

Replicative oncolytic herpes simplex viruses in combination cancer therapies.

Post DE, Fulci G, Chiocca EA, Van Meir EG.

Curr Gene Ther. 2004 Mar;4(1):41-51. Review.

PMID:
15032613
20.

Replicative oncolytic adenoviruses in multimodal cancer regimens.

Post DE, Khuri FR, Simons JW, Van Meir EG.

Hum Gene Ther. 2003 Jul 1;14(10):933-46. Review.

PMID:
12869212
21.

A novel hypoxia-inducible factor (HIF) activated oncolytic adenovirus for cancer therapy.

Post DE, Van Meir EG.

Oncogene. 2003 Apr 10;22(14):2065-72.

PMID:
12687009
22.

Geldanamycin induces degradation of hypoxia-inducible factor 1alpha protein via the proteosome pathway in prostate cancer cells.

Mabjeesh NJ, Post DE, Willard MT, Kaur B, Van Meir EG, Simons JW, Zhong H.

Cancer Res. 2002 May 1;62(9):2478-82.

24.

Culture media for the isolation of campylobacters.

Corry JE, Post DE, Colin P, Laisney MJ.

Int J Food Microbiol. 1995 Jun;26(1):43-76. Review.

PMID:
7662519
25.

The constitutionality of parole departments disclosing the HIV status of parolees.

Post DE.

Wis L Rev. 1992;6:1993-2030. No abstract available.

PMID:
11659885
26.

Problems with Iso-Sensitest agar.

Post DE, Bridson EY.

J Antimicrob Chemother. 1991 Jun;27(6):867-8. No abstract available.

PMID:
1938697

Supplemental Content

Support Center